News

Jul 30, 2024

Positive CHMP opinion on Slenyto® for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs)

We are excited to announce that Neurim Pharmaceuticals received a positive CHMP opinion on Slenyto® (Pediatric Prolonged-Release Melatonin) for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs). This treatment will address additional patients who may benefit with Slenyto® added indication and have good nights and better days.
Read our press release